1 Hot Biotech No One Wants to Buy

Before you go, we thought you'd like these...
Before you go close icon

This episode of The Motley Fool's Market Checkup drills down on the day's hottest headlines and biggest market movers. Market Checkup gives a full examination of a shocking medical device takeover, a hot biotech that can't find an acquirer, a surprise announcement bringing a failed drug, and a big deal in gene sequencing.

In this video, health-care analyst David Williamson discusses Clovis Oncology's failed bid to sell itself. After hanging a for-sale sign on the door, but with no interested parties stepping forward, where does that leave Clovis? Watch and find out along with further details about why its drug pipeline has investors excited.

Looking for more disruptive biotechs?
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

The article 1 Hot Biotech No One Wants to Buy originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow David on Twitter @MotleyDavidMax Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading